3Ayantunde AA, Parsons SL. Pattern and prognostic [actors in patients with malignant ascites: a retrospective studyFJ]. Ann Oncol,2007,18(5) :945-949.
4Becker G,Galandi D,Blum HE. Malignant ascites : systematic re- view and guideline for treatmentFJ]. Eur J Cancer, 2006,42(5): 589-597.
5Worzalla JF,Shih C,Schultz RM. Role of folic acid in modula- ting the toxicity and efficacy of the multitargeted antifolate, LY231514[J]. Anticancer Res, 1998,18(5A) : 3235-3239.
6Pestieau SR, Stuart OA, Sugarbaker PH. Multi-targeted anti{o late (MTA) pharmacokinetics of intraperitoneal administration in a rat model[J]. Eur J Surg Oncol,2000,26(7).-696-700.
7Buque A, Muhialdin JS, Munoz A, et al. Molecular mechanism implicated in pemetrexedinduced apoptosis in human melanoma eells[J]. Mol Cancer,2012,11(1) :25.
8Bareford M D, Hamed H A, Tang Y, et al. Sorafenib enhances pemetrexed eytotoxieity through an autophagy dependent mech- anism in cancer cells[J]. Autophagy,2011,7(10) :1261-1262.
